• Product nameAnti-CHRND antibody
    See all CHRND primary antibodies
  • Description
    Rabbit polyclonal to CHRND
  • Tested applicationsSuitable for: ELISA, IHC-P, WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Dog
  • Immunogen

    A region within synthetic peptide: KKGYNKELRP VAHKEESVDV ALALTLSNLI SLKEVEETLT TNVWIEHGWT, corresponding to N terminal amino acids 36-85 of Human CHRND

  • Positive control
    • Jurkat whole cell lysate


Associated products


Our Abpromise guarantee covers the use of ab49140 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA Use at an assay dependent concentration.

ELISA titre using peptide based assay: 1/15000

IHC-P Use a concentration of 4 - 8 µg/ml.
WB Use a concentration of 1 µg/ml. Detects a band of approximately 59 kDa (predicted molecular weight: 59 kDa). Good results were obtained when blocked with 5% non-fat dry milk in 0.05% PBS-T.


  • FunctionAfter binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
  • Involvement in diseaseDefects in CHRND are a cause of multiple pterygium syndrome lethal type (MUPSL) [MIM:253290]. Multiple pterygia are found infrequently in children with arthrogryposis and in fetuses with fetal akinesia syndrome. In lethal multiple pterygium syndrome there is intrauterine growth retardation, multiple pterygia, and flexion contractures causing severe arthrogryposis and fetal akinesia. Subcutaneous edema can be severe, causing fetal hydrops with cystic hygroma and lung hypoplasia. Oligohydramnios and facial anomalies are frequent.
    Defects in CHRND are a cause of congenital myasthenic syndrome slow-channel type (SCCMS) [MIM:601462]. SCCMS is the most common congenital myasthenic syndrome. Congenital myasthenic syndromes are characterized by muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. SCCMS is caused by kinetic abnormalities of the AChR, resulting in prolonged endplate currents and prolonged AChR channel opening episodes.
    Defects in CHRND are a cause of congenital myasthenic syndrome fast-channel type (FCCMS) [MIM:608930]. FCCMS is a congenital myasthenic syndrome characterized by kinetic abnormalities of the AChR. In most cases, FCCMS is due to mutations that decrease activity of the AChR by slowing the rate of opening of the receptor channel, speeding the rate of closure of the channel, or decreasing the number of openings of the channel during ACh occupancy. The result is failure to achieve threshold depolarization of the endplate and consequent failure to fire an action potential.
  • Sequence similaritiesBelongs to the ligand-gated ion channel (TC 1.A.9) family. Acetylcholine receptor (TC 1.A.9.1) subfamily. Delta/CHRND sub-subfamily.
  • Cellular localizationCell junction > synapse > postsynaptic cell membrane. Cell membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • Acetylcholine receptor delta subunit antibody
    • Acetylcholine receptor subunit delta antibody
    • ACHD_HUMAN antibody
    • ACHRD antibody
    • Cholinergic receptor, nicotinic, delta polypeptide antibody
    • CHRND antibody
    • CMS2A antibody
    • FCCMS antibody
    • Nicotinic acetylcholine receptor delta polypeptide precursor antibody
    • SCCMS antibody
    see all

Anti-CHRND antibody images

  • Anti-CHRND antibody (ab49140) at 1 µg/ml + Jurkat whole cell lysate at 10 µg

    HRP conjugated anti-Rabbit IgG at 1/50,000
    developed using the ECL technique

    Predicted band size : 59 kDa
    Observed band size : 59 kDa
  • Immunohistochemistry of Human kidney lysate tissue at an antibody concentration of 4-8µg/ml using anti-CHRND antibody (ab49140)

References for Anti-CHRND antibody (ab49140)

ab49140 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab49140.
Please use the links above to contact us or submit feedback about this product.